Summary of Business Results for the First Quarter Ended March 31, 2025 (Consolidated)

Company Medrx Co., Ltd. Lidted on the TSE

Stock Code 4586 URL : https://www.medrx.co.jp Representative Yonehiro Matsumura, President & CEO

Contact Takeshi Fujioka, Management Department Director TEL +81-03-3664-9665

Expected starting date of dividend payment : － Preparation of supplementary financial document : None Results briefing : None

1. Consolidated business results for the three months ended March 2025 (January 1, 2025 through March 31, 2025)

   (Rounded down to million yen)

   1. Consolidated results of operations (% change from the previous corresponding period)

      	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent
      Three months ended Mar. 2025	Million yen 2	% -	Million yen -419	% -	Million yen -422	% -	Million yen --429	% -
      Three months ended Mar. 2024	-	-100.0	-176	-	-127	-	-128	-

      (Note) Comprehensive income:

      Three months ended March 2025 : -443 million yen (-%) Three months ended March 2024 : -128 million yen (-%)

      	Net income Per share	Diluted net Income per shar
      	Yen	Yen
      Three months ended Mar. 2025	-9.04	-
      Three months ended Mar. 2024	-3.33	-

      (Note) Diluted net income per share is not applicable due to net loss share

   2. Consolidated financial position

   	Total assets	Net assets	Shareholders' equity ratio
   	Million yen	Million yen	%
   As of Mar. 2025	1,828	1,729	91.4
   As of Dec. 2024	2,275	2,169	92.9

   (Reference) Shareholders' equity :

   As of March 2025 : 1,671million yen

   As of December 2024 : 2,114 million yen

2. Dividends

   	Annual dividend
   	End of 1Q	End of 2Q	End of 3Q	Year-end	Total
   Year ended Dec. 2024 Year ended Dec. 2025	Yen - -	Yen 0.00	Yen -	Yen 0.00	Yen 0.00
   Year ended Dec. 2025 (forecast)		0.00	-	0.00	0.00

3. Forecast of consolidated business results for the fiscal year ending December 2025 (January 1, 2025 through December 31, 2025)

   (% change from the previous year)

   	Net sales		Operating income		Ordinary income		Net income		Net income Per share
   Year ending Dec. 2025	Million yen 122	% -52.5	Million yen -1,335	% -	Million yen -1,335	% -	Million yen -1,350	% -	Yen -28.43

   (Note) Revisions to business forecast for the current quarter: None

   ※ Notes

   1. Changes in significant subsidiaries during the period : None

   2. Application of accounting procedures specific to preparation of the consolidated quarterly financial statements : None

   3. Change in accounting policies, accounting estimates and restatement

      ① Changes in accounting policies associated with revision of accounting standards: : None

      ② Changes in accounting policies other than ① : None

      ③ Changes in accounting estimates : None

      ④ Restatement : None

   4. Shares outstanding (common stock)

① Number of share outstanding at the end of period (treasury stock included) : As of March 2025 47,495,100 shares

As of December 2024 47,495,100 shares

② Treasury stock at the end of period :

As of March 2025 2 share

As of December 2024 2 share

③ Average number of stock during period :

Three months ended March 2025 47,495,100 shares Three months ended March 2024 38,470,748 shares

※ This report is not subject to auditing by a certified public accountant or an audit corporation.

※ Explanation regarding appropriate use of business forecasts and other special instructions

Forecasts regarding future performance in this material are based on information currently available to the company and certain assumptions that the company deems to be reasonable at the time this report was prepared. The company does not make promises about the achievements. Actual results may differ significantly from the forecasts due to various factors.